Portal de Periódicos da CAPES

Incidence, Risk Factors, and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-VEGF for Retinal Diseases

2022; Elsevier BV; Volume: 6; Issue: 11 Linguagem: Inglês

10.1016/j.oret.2022.05.008

2468-7219

Pierre‐Henry Gabrielle, Vuong Nguyen, Louis Arnould, Francesco Viola, Javier Zarranz‐Ventura, Daniel Barthelmes, Catherine Creuzot‐Garcher, Mark C. Gillies, David Squirrell, Jagjit S. Gilhotra, C. Brooijmans, Odette A. M. Tigchelaar-Besling, Amy Cohn, Fred K. Chen, A McGeorge, Sarah E. Welch, Nandor Jaross, P. Peters, Richard Barry, I. W. McLean, Tremeur Guillaumie, A. Miri, Jean‐François Korobelnik, Pierre‐Henry Gabrielle, Michel Weber, Bouteraa Walid, Sarah Tick, S. Valen, Andy P. Field, Sanjeewa Wickremasinghe, C. Dayajeewa, John A. Wells, Rohan W. Essex, Adrian Dunlop, K Michalová, C. M. Ng, Stephanie Young, G. Mimoun, C. Generic, Robyn H. Guymer, Pablo Carnota, C. Torres Borrego, Rosa Dolz‐Marco, Roberto Gallego‐Pinazo, Jordi Esteban, Alfredo Garcı́a-Layana, Manuel Sáenz de Viteri, Joël Uzzan, R. Ferrier, John Ah‐Chan, Lu‐Ping Chow, H Steiner, Ali Amini, G. Clark, Nadia Wittles, P. Windle, J. R. Vingerling, Colin Clement, Mark C. Gillies, Anna Hunt, P. Beaumont, Lynne J. Cottee, Karen Lee, Heather G. Mack, Z. Louw, Jed Lusthaus, Jian Chen, John Landers, Kathryn J Billing, Nilanjan Saha, Stewart Lake, Dania Qatarneh, Russell Phillips, M. Perks, Karim Bañon, M. Guarro, G. Londoño, Cynthia Rethati, Laura Sararols, J. Suárez, Francesco Viola, Sioe Lan Oei, Samantha Fraser‐Bell, R. Montejano-Milner, Carolina Arruabarrena, Edwin K. P. Chong, Simon Lal, A. Higueras, FJ ASCASO, Ana Boned Murillo, M Díaz, Guillermo Pérez Rivasés, S. Alforja Castiella, Carolina Bernal-Morales, Ricardo P. Casaroli‐Marano, Marc Figueras‐Roca, Jordi Izquierdo-Serra, A. Moll Udina, Alba Parrado‐Carrillo, Javier Zarranz‐Ventura, J. Escobar, Francisco Javier Lavid, Marta Álvarez Gil, Pablo Catalán Muñoz, M. Tena Sempere, Luca Cerri, F. Ricci, L. Broc Iturralde, Pamela Campos Figueroa, S. Gómez Sánchez, Xavier Valldeperas, F. Vilaplana, Ester Carreño, N. Munoz Sanz, Néstor Ventura-Abreu, M. Asencio Durán, Pilar Calvo, Jorge Sánchez, Elena Alonso, Ignacio Flores‐Moreno, María García Zamora, E. Ciancas, J.J. González‐López, M. de la Fuente, Mariano Rodríguez Maqueda, Estefanía Cobos, Daniel Lorenzo, Luis Cordovés, M. Acebes, S. Aparicio-Sanchis, Ana Fernández-Hortelano, J. Zarallo-Gallardo, César Azrak, A. Piñero Sánchez, Pablo Almuiña-Varela, L. García García, E. Salinas Martínez, Matthias Marti, A. Campo Gesto, M. Rodriguez Núñez, G. Furness, T.C. Ponsioen, Gabriela Mustata Wilson, L. Manning, Ian L. McAllister, Tim Isaacs, Alessandro Invernizzi, Laurent Castelnovo, Guillaume Michel, Benjamin Wolff, Jennifer Arnold, H. Cass, Derek Chan, Thean Hsiang Tan, Louise O’Toole, Kea‐Tiong Tang, C. Chung, H. Beylerian, Vincent Daïen, C. Chung, Gayatri Banerjee, M. Morgan, Ian Reddie, Jenny V Ongkosuwito, Frank D. Verbraak, Reinier O. Schlingemann, Frank D. Verbraak, Stefano Piermarocchi, Amy Thompson, Jérôme Game, Christopher Thompson, R. Chalasani, Marina Chilov, Adrian T. Fung, S. Nothling, Raymond Chong, Alex P. Hunyor, Christine Younan, Rachel D. Barnes, Dianne Sharp, Andrea L. Vincent, Neil Murray, Sarah Ah-Moye, Charles Hennings, H. Mehta, Pietro Monaco, Chui Ming Gemmy Cheung, Niral Karia, Damien Louis, Sean Every, Philip Lockie, Martin van Hecke, J. van Lith-Verhoeven, C. Chung, Joel Wong, John Grigg, Peter Hinchcliffe, Daniel Barthelmes, E. Diaz De Durana Santa Coloma, Gonzaga Garay‐Aramburu, Stela Vujosevic, Helena Brosa Morros, Mark Daniell, Alex Harper, Lyndell L. Lim, Justin O’Day, Daniel Velázquez-Villoria, Claire Hooper, N. Klaassen-Broekema, Roelof A.J. Smit,

Retinal and Optic Conditions

To report the estimated incidence, probability, risk factors, and 1-year outcomes of rhegmatogenous retinal detachment (RRD) in eyes receiving intravitreal injections (IVTs) of VEGF inhibitors for various retinal conditions in routine clinical practice.Retrospective analysis of data from a prospectively designed observational outcomes registry: the Fight Retinal Blindness!Eyes of patients starting IVTs of VEGF inhibitors (ranibizumab, aflibercept, or bevacizumab) for neovascular age-related macular degeneration, diabetic macular edema, or retinal vein occlusion from January 1, 2006, to December 31, 2020. All eyes that developed RRD within 90 days of IVTs were defined as cases with RRD and were matched with control eyes.Estimated incidence, probability, and hazard ratios (HRs) of RRD were measured using Poisson regression, Kaplan-Meier survival curve, and Cox proportional hazards models. Locally weighted scatterplot smoothing curves were used to compare visual acuity (VA) between cases and matched controls.Estimated incidence of RRD.We identified 16 915 eyes of 13 792 patients who collectively received 265 781 IVTs over 14 years. Thirty-six eyes were reported to develop RRD over the study period. The estimated incidence (95% confidence interval [CI]) per year per 1000 patients and per 10 000 injections was 0.77 (0.54-1.07) and 1.36 (0.95-1.89), respectively. The probability of RRD did not significantly increase at each successive injection (P = 0.95) with the time of follow-up. Older patients (HR [95% CI] = 1.81 [1.21-3.62] for every decade increase in age, P < 0.01) were at a higher risk of RRD, whereas patients with good presenting VA (HR [95% CI] = 0.85 [0.70-0.98] for every 10-letter increase in VA, P = 0.02) were at a lower risk. Neither the type of retinal disease (P = 0.52) nor the VEGF inhibitor (P = 0.09) was significantly associated with RRD risk. Cases with RRD lost 3 lines of vision on average compared with the prior RRD VA and had significantly fewer injections than matched controls over the year after the RRD.Rhegmatogenous retinal detachment is a rare complication of VEGF inhibitor IVT in routine clinical practice with poor visual outcomes at 1 year.